Navigation Links
NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
Date:10/4/2011

BETHESDA, Md., Oct. 4, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it will be presenting at the second annual Cancer Immunotherapy: A Long-Awaited Reality Conference on Thursday, October 6, at the New York Academy of Medicine in New York City.  The single-day conference unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy that is now coming of age.

Dr. Anthony Maida, COO, and Mr. Leslie J. Goldman, Sr. Vice President for Business Development, of NORTHWEST BIO will be making the presentation. They will be presenting the science of DCVax®, the promising clinical data generated to date, and the progress of the Company's pipeline of multiple individualized cancer vaccine products.  They will indicate how NORTHWEST BIO's developing immunotherapy products hold the promise of treating cancers more effectively than the current standard of care, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the US and Europe.

Ms. Linda Powers, CEO of NORTHWEST BIO said, "This topic and conference are particularly timely in view of yesterday's Nobel Prize in Medicine for certain key discoveries about the immune system – especially about the critical role of dendritic cells.  At NORTHWEST BIO, we have developed medical treatments for cancer using these same dendritic cells, whose discovery by Dr. Ralph Steinman now has earned the Nobel Prize.  Our medical treatments are one of the first personalized medicines to apply this potential: they make use of the patient's own dendritic cells, which are activated and "educated" to mobilize the immune system to attack that patient's particular cancer." 

"We have been developing these dendritic cell treatments for over a decade and have now reached late s
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
2. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
3. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
4. Northwest Biotherapeutics Announces Change and Expansion of Management Team
5. Northwest Biotherapeutics Announces Series of Financing Arrangements
6. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
7. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
8. Northwest Biotherapeutics Addresses Recent Market Activity
9. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
10. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
11. BioSpace Highlights the Northwests Growing Life Science Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... May 24, 2013 Many factors impact ... uptake or efflux transporters at the blood-tissue barrier. Even ... to unbound fractions in the tissue rather than the ... disposition challenges is required to guide lead optimization, predict ... any species-dependent variables that may impact the likely human ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... 19 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... II study with intramuscular (i.m.) injection of ... of seasonal and,life-threatening influenza. (Logo: ... a randomized, double-blind, placebo-controlled clinical,trial designed to ...
... 19 Health and Human,Services Secretary Mike ... the goal of personalized health care and ... and health care delivery should be,aligned to ... time" for each,individual patient., The report, ...
... Life,Sciences, Inc. (Nasdaq: CALP ) today announced that ... New York City will be webcast on,Tuesday, September 25 ... Caliper, will be providing an update on the company,s ... http://www.caliperls.com and clicking on the,link for the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7HHS Issues First Department-Wide Report on Personalized Health Care 2HHS Issues First Department-Wide Report on Personalized Health Care 3
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... release is available in Spanish . , Adolescents ... condition and regular physical activity present increased levels of insulin ... diabetes, appetite control and energy expenditure. This was the conclusion ... Physiology of the University of Granada . Further, after ...
... increasingly common and effective for operating inside the human ... tools inserted into the body of the patient, the ... determining the success of the operation. A team of ... a $2.3 million federal grant to develop a touch-sensitive ...
... next generation sequencing (NGS) and Certified Service Provider for ... a leading company in complex analysis and interpretation of ... complete human exome array, based on Roche NimbleGen sequence ... comprehensive service for human exome capture, targeted re-sequencing and ...
Cached Biology News:Children in good shape have better appetite control and energy expenditure 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 2Designing touch-sensitive virtual reality tools to train and test tomorrow's surgeons 3Eurofins MWG Operon and Genomatix developed most complete human exome array 2
...
Collected from 8-12 week-old New Zealand or Californian rabbits....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Silica bead method is an economic method of DNA extraction from agarose...
Biology Products: